Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744647 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
A Phase 2 study of Kidney Transplantation and Antibody-mediated Rejection, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06744647: Recruiting Phase 2 study of Kidney Transplantation and Antibody-mediated Rejection, sponsored by Alexion Pharmaceuticals.
NCT06744647 is a Phase 2 study of Kidney Transplantation and Antibody-mediated Rejection that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 45 participants, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06744647, a Phase 2 study of Kidney Transplantation and Antibody-mediated Rejection, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALXN2030
Study Locations (20)
New York
- Research Site - New York
- Research Site - New York
- Research Site - New York
- Research Site - New York
California
- Research Site - Los Angeles
- Research Site - Orange
Michigan
- Research Site - Ann Arbor
- Research Site - Detroit
Texas
- Research Site - Dallas
- Research Site - Houston
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Scottsdale
Florida
- Research Site - Tampa
Georgia
- Research Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2028-11-07 |
| Phase | Phase 2 |
What NCT06744647 shows while recruiting
NCT06744647 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (83% lower).
The record links to 4 conditions, with Kidney Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06744647 names 20 study sites across 14 states, led by New York, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06744647 about?
NCT06744647 is a clinical study titled "Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation". The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
What is the current status of trial NCT06744647?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-03-07. Estimated completion is 2028-11-07.
What conditions does trial NCT06744647 study?
This clinical trial studies the following conditions: Kidney Transplantation, Antibody-mediated Rejection, Biopsy-proven Histologic Scores, AMR.
What interventions are being tested in trial NCT06744647?
The interventions under investigation include: Placebo (DRUG), ALXN2030 (DRUG).
Who is sponsoring clinical trial NCT06744647?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744647 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06744647's enrollment target sits among peer trials
45 25th of 33 higher than 8 of 33 other Kidney Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
RECRUITING · Phase 2
-
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
COMPLETED · Phase 2
-
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
COMPLETED · Phase 2
-
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI